Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...
Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...
Shares of Biogen Inc. BIIB slid 5.91% to $122.98 Friday, on what proved to be an all-around rough trading session for the ...
Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy.Don't Miss Our End of Quarter Offers: Discover the latest stocks ...
Pharmaceutical Technology on MSN4d
Organon acquires Actemra biosimilar’s US rights from BiogenBio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.
We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
Shares of Biogen Inc. shed 3.52% to $132.03 Tuesday, on what proved to be an all-around mixed trading session for the stock ...
Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...
Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback